Keyphrases
Acute Myeloid Leukemia
100%
Phase II Study
70%
Myelodysplastic Syndrome
51%
Chronic Myeloid Leukemia
51%
Venetoclax
44%
Myelofibrosis
44%
Gemtuzumab Ozogamicin
44%
Acute Leukemia
37%
Clonal Hematopoiesis
34%
Standard of Care
34%
Tumor Protein p53 (TP53)
32%
Leukemia
29%
Ruxolitinib
28%
Monotherapy
27%
Confidence Interval
26%
Hematopoiesis
25%
Leukemia Patients
24%
Early Management
22%
Early Symptoms
22%
Diffuse Alveolar Hemorrhage
22%
Pleural Effusion
22%
High-risk Myelodysplastic Syndrome
22%
Complication Management
22%
PPM1D
22%
Hematological Malignancies
22%
Quizartinib
22%
Phase II Clinical Trial
22%
Menin Inhibitors
22%
Early Signs
22%
Single Center
22%
Antileukemic Activity
22%
Richter Transformation
22%
Intensivist
22%
Pracinostat
22%
Renal Cell Carcinoma
22%
Phase 1/2 Study
22%
Eltrombopag
22%
Leukostasis
22%
Novel Therapies
22%
Cytokine Release Syndrome
22%
Peptide Receptor Radionuclide Therapy
22%
Chronic Lymphocytic Leukemia
22%
Life-threatening Complications
22%
Antileukemic Therapy
22%
Improved Survival
22%
Pathophysiology
22%
Oral Decitabine
22%
Cedazuridine
22%
Low-dose Cytarabine
22%
E14a3
22%
Medicine and Dentistry
Acute Myeloid Leukemia
55%
Myelodysplastic Syndrome
51%
Venetoclax
44%
Myelofibrosis
44%
Hematopoiesis
44%
Leukemia
36%
Diseases
35%
Clinical Trial
34%
Hypomethylating Agent
29%
Ruxolitinib
28%
Janus Kinase
28%
Monotherapy
26%
Acute Leukemia
25%
Chronic Myelogenous Leukemia
24%
Pleura Effusion
22%
Exon
22%
Myeloproliferative Neoplasm
22%
Hematologic Malignancy
22%
Pracinostat
22%
Intensivist
22%
Clear Cell Renal Cell Carcinoma
22%
Clinician
22%
Chronic Myelomonocytic Leukemia
22%
Eltrombopag
22%
Cedazuridine Plus Decitabine
22%
Radionuclide Therapy
22%
Richter's Transformation
22%
Peptide Receptor
22%
Methionine
22%
B-Cell Chronic Lymphocytic Leukemia
22%
Janus Kinase Inhibitor
22%
Immune Checkpoint Blockade
22%
Combination Therapy
22%
Immune Checkpoint Inhibitor
22%
Cytopenia
19%
NPM1
14%
Arm
13%
Malignant Neoplasm
13%
Pulmonary Hemorrhage
11%
Philadelphia 1 Chromosome
11%
Physical Disease by Body Function
11%
Chemoimmunotherapy
11%
Leukostasis
11%
Cytokine Release Syndrome
11%
Pathophysiology
11%
Tumor Lysis Syndrome
11%
Acute Lymphoblastic Leukemia
11%
Myeloid Malignancy
9%
Platelet
8%
Odds Ratio
8%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
92%
Myelodysplastic Syndrome
66%
Venetoclax
44%
Gemtuzumab Ozogamicin
44%
Clinical Trial
36%
Leukemia
27%
Monotherapy
27%
Acute Leukemia
25%
Receptor
22%
Cytarabine
22%
Quizartinib
22%
Chronic Myelomonocytic Leukemia
22%
Eltrombopag
22%
Cedazuridine Plus Decitabine
22%
Radioisotope
22%
Methionine
22%
Azacitidine
22%
Chronic Lymphatic Leukemia
22%
Janus Kinase Inhibitor
22%
Combination Therapy
22%
Arsenite
22%
Arsenous Acid
22%
Promyelocytic Leukemia
22%
Retinoic Acid
22%
Myelofibrosis
22%
Diseases
19%
Cytopenia
19%
Overall Survival
16%
Physical Disease by Body Function
11%
Leukostasis
11%
Pathophysiology
11%
Cytokine Release Syndrome
11%
Lung Hemorrhage
11%
Tumor Lysis Syndrome
11%
Sepsis
9%
Remission
9%
Infection
8%
Cedazuridine
7%
Decitabine
7%
Protein Kinase Fer
7%
Adverse Event
6%
Thrombocytopenia
6%
Neutropenia
6%
Neuroendocrine Tumor
6%
Leukocytosis
6%
Ruxolitinib
6%
Chemotherapy
5%
Prednisone
5%
Cyclophosphamide
5%
Vincristine
5%